Loss and gain of bone in spondyloarthritis: what drives these opposing clinical features? (2020)
https://pubmed.ncbi.nlm.nih.gov/33240403/

Prevalence and predictors of tumour necrosis factor inhibitor persistence in psoriatic arthritis (2018)
https://pubmed.ncbi.nlm.nih.gov/29077973/

Secukinumab, a human anti-interleukin-17A monoclonal antibody, in patients with psoriatic arthritis (FUTURE 2): a randomised, double-blind, placebo-controlled, phase 3 trial (2015)
https://pubmed.ncbi.nlm.nih.gov/26135703/

An open-label study of zoledronic acid (Aclasta 5 mg iv) in the treatment of ankylosing spondylitis (2014)
https://pubmed.ncbi.nlm.nih.gov/24521738/

Factors influencing work disability in psoriatic arthritis: first results from a large UK multicentre study (2014)
https://pubmed.ncbi.nlm.nih.gov/25125591/

‘Sink or swim’: an evaluation of the clinical characteristics of individuals with high bone mass (2012)
https://pubmed.ncbi.nlm.nih.gov/21455762/